Effect of Highly Active Antiretroviral Therapy (HAART) on Human Immunodeficiency Virus Disease Pathogenesis and Progression

K V Ramana

American Journal of Public Health Research. 2014, 2(3), 68-74
DOI: 10.12691/AJPHR-2-3-1

Review Article

Effect of Highly Active Antiretroviral Therapy (HAART) on Human Immunodeficiency Virus Disease Pathogenesis and Progression

K V Ramana^1,

¹Department of Microbiology, Prathima Institute of Medical Sciences, Karimnagar, Andhrapradesh

Pub. Date: April 13, 2014

Full Text PDF

Cite this paper

K V Ramana. Effect of Highly Active Antiretroviral Therapy (HAART) on Human Immunodeficiency Virus Disease Pathogenesis and Progression. American Journal of Public Health Research. 2014; 2(3):68-74. doi: 10.12691/AJPHR-2-3-1

Abstract

Human immunodeficiency virus (HIV), the causative agent of Acquired Immunodeficiency Syndrome (AIDS) was discovered way back in 1983. More than three decades since its discovery, HIV infection diagnosis, treatment and management has been a big challenge to the medical field. HIV infection is attributed to cause compromised T-cell and B-cell immunity, promote different malignancies and the infected individuals are at risk of acquiring other viral, bacterial, fungal and parasitic infections. HIV disease progression was found different in infected population, where few HIV infected patients develop AIDS in less than 5 years and are called as early progressors, HIV infected population in whom development of AIDS is slow and may remain normal up to 10 years are termed as late progressors and patients in whom the symptoms of AIDS are not seen even after 10-15 years are labeled as long term non-progressors. The variability in disease progression is not completely understood. After the discovery of HAART, the mortality of the HIV infected population has significantly reduced but the morbidity attributed to HAART has remained as a serious concern. From being a life threatening infection HIV has now become a chronic infection, where patients live their natural life years with the HAART therapy. Among the most significant changes in HIV infection and pathogenesis is the development of non-infectious complications attributed to the HIV infection, HAART therapy, other demographic factors and co-morbidities. Other factors that influence the disease pathogenesis and progression include chronic immune activation, drug resistance and toxic side effects of HAART therapy. Among this Immune activation plays a key role in the pathogenesis and progression of HIV infection.

Keywords

HIV disease pathogenesis, HAART, immune activation, non-AIDS related complications

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Deeks SG. Immune dysfunction, inﬂammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009; 17:118-23.

[2]	K V Ramana. Are we close enough to get rid of AIDS: Insights in to impact of Human Immunodeficiency virus (HIV) infection post Highly Active Antiretroviral therapy (HAART) Era. International Journal of Molecular Medical Science, 2013; 3(5): 25-29.

[3]	K V Ramana and Ratna rao. Human Immunodeficiency Virus disease management in Highly Active Anti-Retroviral Therapy era: a comprehensive review Ann of Trop Med Public Health 2013; 6(1): 5-9.

[4]	Ramana, K V. "Markers of HIV-1 Disease Progression and Treatment Response in Highly Active Antiretroviral Therapy (HAART) Era: A Review." American Journal of Infectious Diseases and Microbiology 1.5 (2013): 96-100.

[5]	Ramana K V, Rao R. Noninfectious complications in HIV disease: Need for rational changes in HIV disease management in the highly active antiretroviral therapy era. Ann Trop Med Public Health 2013; 6: 383-5.

[6]	Paul A Volberding, Steven G Deeks. Antiretroviral therapy and management of HIV infection. Lancet 2010; 376: 49-62.

[7]	K. V. Ramana and S. K. Mohanty Opportunistic intestinal parasites and TCD4⁺ cell counts in human immunodeficiency virus seropositive patients. J Med Microbiol 2009. 58: 1664-1666.

[8]	Ramana K V. HIV Disease Management in the Highly Active Antiretroviral Therapy (HAART) Era. J Medical Microbiol Diagnosis 2012; 1:e101.

[9]	Ascher MS and Sheppard HW: AIDS as immune system activation: A model for pathogenesis. Clin Exp Immunol 1988; 73(2):165-167.

[10]	Hazenberg MD, Hamann D, Schuitemaker H, and Miedema F: T cell depletion in HIV-1 infection: how CD4 + T cells go out of stock. Nat Immunol 2000; 1(4): 285.

[11]	Ramana K V, Jagadeeswhwara chary, Sabitha V, S K Mohanty, Ratna Rao. Role of Hematological and Alternate Markers in Human Immunodeficiency Virus Disease Progression. American Medical Journal 2010; 1 (2): 84-87.

[12]	K V Ramana, V Sabitha, Ratna Rao. A Study of Alternate Biomarkers in HIV Disease and Evaluating their Efficacy in Predicting T CD4+ cell counts and Disease Progression in resource poor settings in Highly Active Antiretroviral Therapy (HAART) Era. Journal of Clinical and Diagnostic Research [serial online] 2013 July [cited: 2013 Jul 5]; 7:1332-1335.

[13]	Kandi Venkataramana. A Study of Biological Markers in HIV Disease Progression and Management in the Highly Active Antiretroviral Therapy (HAART) Era, American Journal of Bioscience and Bioengineering. 2013; 1(2): 24-37.

[14]	Ramana KV, Ratna Rao, Sabitha Abnormal Levels of γ-Glutamyl Transpeptidase (GGTP), ALT, AST in Human Immunodeficiency Virus-1(HIV-1) Infection. Biochem Physiol 2012; 1:101.

[15]	Ramana K V, Rao R, Kandi S, Singh PA, Kumar VP. Elevated activities of serum lactate dehydrogenase in human immunodeficiency virus sero-positive patients in highly active antiretroviral therapy era. J Dr NTR Univ Health Sci 2013;2:162-6.

[16]	Ramana KV, Ratna Rao, Sabitha, Venugopal B, Rafi MD, et al. Biochemical Parameters in Human Immunodeficiency Virus Disease Progression. J Medical Microbiol Diagnosis 2012; 1:103.

[17]	K V Ramana etal, Seroprevalence of blood-borne viral infections in post HAART era at a tertiary care hospital in south India: A five year trend analysis (2008-2012) and a comprehensive review. British Journal of Medicine and Medical Research 2013; 3 ( 4) : 1929-1937.

[18]	José Antonio Mata-Marín, Jesús Gaytán-Martínez, Bernardo Horacio Grados-Chavarría, José Luis Fuentes-Allen, Carla Ileana Arroyo-Anduiza and Alfredo Alfaro-Mejía. Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study. Virology Journal 2009, 6:181.

[19]	Jalbert E, Crawford TQ, D’Antoni ML, Keating SM, Norris PJ, et al. IL-1Β Enriched Monocytes Mount Massive IL-6 Responses to Common Inflammatory Triggers among Chronically HIV-1 Infected Adults on Stable Anti-Retroviral Therapy at Risk for Cardiovascular Disease. PLoS ONE 2013; 8(9): e75500.

[20]	Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010; 50: 98-105.

[21]	The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372: 293-99.

[22]	Dr Aberg Management of Dyslipidemia and Other Cardiovascular Risk Factors in HIV-Infected Patients: Case-based Review. Top HIV Med. 2006;14(4):134-139.

[23]	N Vanker. The use of the full blood count and differential parameters to assess immune activation levels in asymptomatic, untreated HIV infection. S Afr Med J 2014; 104(1):45-48.

[24]	Karen Ingrid Tasca, Sueli Aparecida Calvi and Lenice do Rosário de Souza. Immunovirological parameters and cytokines in HIV infection Rev Soc Bras Med Trop 2012; 45(6):663-669.

[25]	Marta Catalfamo, Michele Di Mascio, Zonghui Hu, Sharat Srinivasula, Vishakha Thaker, Joseph Adelsberger. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. PNAS 2008; 105 (50): 19851-19856.

[26]	Keating SM, Jacobs ES, Norris PJ. Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development. Cytokine Growth F R 2012; 23: 193-206.

[27]	Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001; 12: 133-150. Viral induction suppression.

[28]	Roberts L, Passmore JS, Williamson C, Little F, Bebell LM, Mlisana K, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010; 24:819-831.

[29]	Wren L, Parsons MS, Isitman G, Center RJ, Kelleher AD, Stratov I, et al. Influence of cytokines on HIV-specific antibody-dependent cellular cytotoxicity activation profile of natural killer cells. PLoS ONE 2012; 7:e38580.

[30]	Clerici M, Shearer GM. A TH-1/TH-2 switch is a critical step in etiology of HIV infection. Immunol Today 1993; 14:107-111.\

[31]	Clerici M, Sarin A, Coffman RL, Wynn TA, Blatt SP, Hendrix CW , et al. Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci USA 1994; 91: 1181111815.

[32]	Stylianou E, Aukrust P, Kvale D, Müller F, Frøland SS. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression-down-regulatory effect of potent antiretroviral therapy. Clin Exp Immunol 1999; 116:115-120.

[33]	Li Y, Ling W, Xu H, Wang M, Wu C. The activation and dynamics of cytokine expression by CD4+ T cells and AIDS progression in HIV-1-infected Chinese individuals. Microb Pathogenesis 2012; 53:189-197.

[34]	Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 4781-4789.

[35]	Gay C, Dibben O, Anderson JA, Stacey A, Mayo AJ, Norris PJ, et al. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS ONE 2011; 6:e19617.

[36]	Papagno L, Spina CA, Marchant A, et al. Immune activation and CD8(+) T-cell diﬀerentiation towards senescence in HIV-1 infection. PLoS Biol 2004; 2: e20.

[37]	Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104: 942-47.

[38]	Regidor DL, Detels R, Breen EC, Widney DP, Jacobson LP, Palella F, et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 2011, 25:303-31.

[39]	Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.

[40]	Sachdeva RK, Wanchu A, Bagga R, Malla N, Sharma M. Effect of non-nucleoside reverse transcriptase inhibitors on cytokine, chemokine, and immunoglobulin profiles in serum and genital secretions of HIV-infected women. J Interferon & Cytokine Res 2010; 30:299-310.

[41]	Haissman JM, Vestergaard LS, Sembuche S, Erikstrup C, Mmbando B, Mtullu S, et al. Plasma Cytokine Levels in Tanzanian HIV-1-Infected Adults and the Effect of Antiretroviral Treatment. J Acquir Immune Defic Syndr 2009; 52:493-49.

[42]	Resino S, Belloan JM, Sanchez-Ramoa AS, Gurbindo D, Muñóz-Fernandez MA. Clinical relevance of cytokine production in HIV-1 infection in children on antiretroviral therapy. Scand J Immunol 2000; 52:634-640.

[43]	Moore KW, O' Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu Rev Immunol 1993; 11:165-190.

[44]	Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150:353-360.

[45]	Cozzi-Lepri A, French MA, Baxter J, Okhuysen P, Plana M, Neuhaus J, et al. Resumption of HIV replication is associated with monocyte/ macrophage derived cytokine and chemokine changes: results from a large international clinical trial. AIDS 2011; 25:1207-1217.

[46]	Wiercinska-Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Plasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patients. Microbes Infect 2004; 6:1273-1277.

[47]	Torre D, Pugliese A. Interleukin-18: a proinflammatory cytokine in HIV-1 infection. Curr HIV Res 2006; 4:423-430.

[48]	Maek-A-Nantawat W, Buranapraditkun S, Klaewsongkram J, Ruxrungthum K. Increased interleukin-17 production both in helper T Cell subset Th17 and CD4negative T cells in human immunodeficiency virus infection. Viral Immunol 2007; 20:328.

[49]	Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007; 19:652-657.

[50]	Murray JS, Elashoﬀ MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. The use of plasma HIV RNA as a study endpoint in eﬃcacy trials of antiretroviral drugs. AIDS 1999; 13: 797-804.

[51]	Nigam P, Kwa S, Velu V, Amara RR. Loss of IL-17–Producing CD8 T Cells during Late Chronic Stage of Pathogenic Simian Immunodeficiency Virus Infection. J Immunol 2011; 186:745-753.

[52]	Alcaide ML, Parmigiani A, Pallikkuth S, Roach M, Freguja R, et al. Immune Activation in HIV-Infected Aging Women on Antiretrovirals— Implications for Age-Associated Comorbidities: A Cross-Sectional Pilot Study. PLoS ONE 2013; 8(5): e63804.

[53]	Barqasho B, Nowak P, Tjernlund A, Kinloch S, Goh LE, Lampe F, et al. Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption. British HIV Association. HIV Med 2009; 10:94-102.

[54]	Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.

[55]	Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140:883-899.

[56]	Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS. 2010; 5:498-503.

[57]	Simonetta F and Bourgeois C. CD4CFOXP3C regulatory Tcell subsets in human immunodeﬁciency virus infection. Front. Immunol. 2013; 4:215.

[58]	Eller MA, Blom KG, Gonzalez VD, Eller LA, Naluyima P, et al. Innate and Adaptive Immune Responses Both Contribute to Pathological CD4 T Cell Activation in HIV-1 Infected Ugandans. PLoS ONE 2011; 6(4): e18779.

[59]	Nagy LH, Grishina I, Macal M, Hirao LA, Hu WK, et al. Chronic HIV Infection Enhances the Responsiveness of Antigen Presenting Cells to Commensal Lactobacillus. PLoS ONE 2013; 8(8): e72789.

[60]	Chevalier MF, Petitjean G, Dunyach-Remy C, Didier C, Girard P-M, et al. The Th17/Treg Ratio, IL-1RA and sCD14 Levels in Primary HIV Infection Predict the T-cell Activation Set Point in the Absence of Systemic Microbial Translocation. PLoS Pathog 2013 ; 9(6): e1003453.

[61]	XIAO Jian, QIAN Ke-lei, CAO Qing-hua, QIU Chen-li, QIU Cao, XUE Yi-le, ZHANG Xiao-yan, ZHONG Ping, XU Jian-qing, LI Ming-yuan and WANG Ying. HLA- DR expression on regulatory T cells is closely associated with the global immune activation in HIV-1 infected subjects naïve to antiretroviral therapy. Chin Med J 2011; 124(15):2340-2346.

[62]	Read SW, DeGrezia M, Ciccone EJ, DerSimonian R, Higgins J, et al. The Effect of Leflunomide on Cycling and Activation of T-Cells in HIV-1-Infected Participants. PLoS ONE 2010; 5(8): e11937.

[63]	Rey-Cuille MA, Berthier JL, Bomsel-Demontoy MC, Chaduc Y, Montagnier L, Hovanessian AG, Chakrabarti LA. Simian immunodeficiency virus replicates to high levels in sooty mangabeys without inducing disease. J Virol 1998; 72:3872-86.

[64]	Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, Champagne P, Bart PA, Chave JP, Lazzarin A, Pantaleo G. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109:681-8.

[65]	Gilad Doitsh, Nicole L. K. Galloway, Xin Geng, Zhiyuan Yang, Kathryn M. Monroe, Orlando Zepeda, Peter W. Hunt, Hiroyu Hatano, Stefanie Sowinski, Isa Muñoz-Arias & Warner C. Greene. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature (2013).

[66]	Nichole R. Klatt, Lauren A. Canary, Xiaoyong Sun, Carol L. Vinton, Nicholas T. Funderburg, David R. Morcock, Mariam Quiñones, Clayton B. Deming, Molly Perkins, Daria J. Hazuda, Michael D. Miller, Michael M. Lederman, Julie A. Segre, Jeffrey D. Lifson, Elias K. Haddad, Jacob D. Estes and Jason M. Brenchley. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest. 2013; 123(2):903-907.

[67]	Hontelez JA, Lurie MN, Newell ML, et al. Ageing with HIV in South Africa. AIDS 2011; 25: 1665-67.

[68]	Serena Spudich and Francisco Gonza´ lez-Scarano HIV-1-Related Central Nervous System Disease: Current Issues in Pathogenesis, Diagnosis, and Treatment. Cold Spring Harb Perspect Med 2012; 2:a007120.

[69]	Shikuma CM, Chow DC, Gangcuangco LMA, Zhang G, Keating SM, et al. Monocytes Expand with Immune Dysregulation and Is Associated with Insulin Resistance in Older Individuals with Chronic HIV. PLoS ONE 2014 ; 9(2): e90330.

[70]	Hsu et al.: Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Research and Therapy 2013 10:29.

[71]	Steven G Deeks, Sharon R Lewin, Diane V Havlir The end of AIDS: HIV infection as a chronic disease. Lancet 2013; 382: 1525-33.

[72]	Sharon R. Lewin and Christine Rouzioux. HIV cure and eradication: how will we get from the laboratory to effective clinical trials? AIDS 2011, 25:885-897.

[73]	Sandler, Netanya G and Sereti, Irini. Can early therapy reduce inflammation? Current Opinion in HIV & AIDS January 2014 - Volume 9 - Issue 1 - p 72-79.

[74]	Irini Sereti, Richard M. Dunham, John Spritzler, Evgenia Aga, Michael A. Proschan, Kathy Medvik et al IL-7 administration drives T cell- cycle entry and expansion in HIV-1 infection. 2009; 113: 6304-6314.

[75]	Sereti I, Estes JD, Thompson WL, Morcock DR, Fischl MA, et al. Decreases in Colonic and Systemic Inflammation in Chronic HIV Infection after IL-7 Administration. PLoS Pathog 2014; 10(1): e1003890.

[76]	Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeﬁciency virus care in the United States. Med Care 2006; 44: 990-97.

[77]	Bendavid E, Ford N, Mills EJ. HIV and Africa’s elderly: the problems and possibilities. AIDS 2012; 26 (suppl 1): S85-91.

[78]	Bor J, Herbst AJ, Newell ML, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339: 961-65.